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To the Editor,
Multidrug resistance (MDR) is defined as an acquired
nonsusceptibility to at least one agent in three or more
antimicrobial classes (1). Overexpression of the multidrug
efflux pump AcrAB-TolC has been shown to directly
contribute to MDR in Escherichia coli and controls the
susceptibility of E. coli strains to many structurally unrelated
antibiotics, including β-lactams, fluoroquinolones
(FQs), and aminoglycosides (2). E. coli, characterized
by extensive antibiotic resistance, is an important public
health issue, and a high risk for the treatment of infectious
diseases can arise from recommended available dosage
regimens. This is one of the most challenging problems
in the study of infectious diseases. In cases involving
a lack of effective agents, a combination of two or more
antibiotics is often used with the expectation of achieving
a synergistic effect (3). Therefore, interactions among
FQ, β-lactams, aminoglycosides, and polymyxin were
examined as a part of the approach to the resistance
problem. Drug combination studies were performed using
the checkerboard and time-kill methods. The fractional
inhibitory concentration index (FICi) was interpreted as
follows: FICi ≤ 0.5 = synergy; FICi > 4.0 = antagonism;
and FICi > 0.5–4 = no interaction. Clinical E. coli isolates
from various animals were collected from the Animal
Hospital of the Faculty of Veterinary Medicine (Bursa,
Turkey). Five representative E. coli isolates were chosen
from 24 different random amplified polymorphic DNA
(RAPD) patterns based on MDR profile and genotype.
Broth microdilution testing was performed to determine
the MICs of nalidixic acid (NAL), enrofloxacin (ENR),
danofloxacin (DAN), ciprofloxacin (CIP), orbifloxacin
(ORB), gatifloxacin (GAT), ampicillin (AMP), ceftiofur
(CEF), cefotaxime (CTX), ceftriaxone (CRO), cefepime
(FEP), sulfamethoxazole (SMX), trimethoprim (TMP),
gentamicin (GEN), tetracycline (TET), oxytetracycline
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(OTC), erythromycin (ERY), chloramphenicol (CHL),
and colistin (CST) according to the guidelines of the
Clinical Laboratory Standards Institute (4). Antimicrobial
dilutions were prepared in CAMHB, and inocula with a
density equivalent to a 0.5 McFarland standard were added
to wells containing the antimicrobials. PCR and qRT-PCR
were used to characterize the molecular mechanisms of
resistance.
The sum of the MIC values ranged from 1133.58 to
1474.96 µg/mL. E. coli isolates had two single (Se83→Leu,
Ser83→Thr) and two double (Ser83→Leu+Ser80→Ile,
Ser83→Leu+Asp87→Glu) topoisomerase mutations. In
addition, one isolate (E. coli E306) contained the oqxB
gene. An increased expression of marA, acrB, and soxS
was detected in two, two, and five isolates, respectively;
a decreased expression of ompF was detected in one
isolate (E. coli E246). The FICi values of the β-lactam/FQ,
β-lactam/aminoglycosides, β-lactam/polymyxin, and FQ/
polymyxin combinations for multidrug-resistant E. coli
isolates ranged from 0.09 to 2.03, 0.06 to 1.50, 0.01 to 2.03,
and 0.15 to 1.25, respectively. The incidence of synergy
and no interaction of 16 different combinations was 68%
and 32%, respectively. CEF/ENR, CEF/DAN, CEF/GEN,
CEF/CST, CST/CIP, and CST/DAN exhibited synergistic
activity against all E. coli isolates tested.
The in vitro activity of the combinations against
multidrug-resistant E. coli isolates was verified by timekill assay. Synergy was defined as a ≥2 log10 decrease in the
colony count at 6 or 24 h, with the combination treatment
compared with the initial inoculum. The incidence of
synergy for the combinations at 6 and 24 h was 51.5%
and 37.5%, respectively. At the 6-h incubation time point,
FEP/ENR, FEP/DAN, CEF/CIP, CEF/DAN, FEP/CST,
CRO/CST, CIP/CST, ENR/CST, and DAN/CST therapies
resulted in a ≥2 log10 reduction in viable counts against at
least three of the five E. coli isolates. At the 24-h incubation
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time point, FEP/ENR, FEP/DAN, CEF/DAN, FEP/CST,
and ENR/CST therapies resulted in a ≥2 log10 reduction in
viable counts against at least three of the 5 E. coli isolates.
These results showed that for E. coli, the synergy incidence
detected by the checkerboard method is higher than that
by the time-kill method, and the CEF/DAN combination
exhibited synergistic activity in the checkerboard method
and also at 6 h and 24 h of the time-kill assays. These data
strongly support that antimicrobial combinations between

different groups can be considered for effective inhibition
of multidrug-resistant E. coli containing various resistance
determinants.
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